Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
The hMLH1 −93G>A Promoter Polymorphism is Associates with Outcomes in Oral Squamous Cell Carcinoma Patients
Ist Teil von
Annals of surgical oncology, 2014-12, Vol.21 (13), p.4270-4277
Ort / Verlag
Boston: Springer US
Erscheinungsjahr
2014
Quelle
MEDLINE
Beschreibungen/Notizen
Background
The aim of this study was to investigate the impact of
hMLH1
polymorphisms on treatment outcomes in patients with oral squamous cell carcinoma (OSCC).
Methods
Genotypings were performed by direct DNA sequencing in peripheral blood leukocytes from 185 male OSCC patients. Patients received primary surgery with or without adjuvant radiotherapy. Two
hMLH1
tag single nucleotide polymorphisms (SNPs)—rs1800734 (−93G>A in the promoter) and rs1540354 (in the third intron)—were chosen from the HapMap project. Overall survival (OS) and disease-free survival (DFS) were compared between different genotypes.
Results
The
hMLH1
rs1800734 and rs1540354 polymorphisms were in weak linkage disequilibrium (
r
2
= 0.456). OSCC patients with the rs1800734 AA genotype had a significantly poor prognosis in both OS and DFS. This SNP can also predict the outcomes of OSCC patients with postoperative adjuvant radiotherapy, especially in advanced stage; however, no significant differences in patient outcomes were found for the
hMLH1
rs1540354 genotypes.
Conclusions
Our results demonstrate that the
hMLH1
−93G>A SNP is found to be associated with patient outcomes in OSCC. This SNP can also predict their treatment outcome of radiotherapy.